Use and outcome of minimally invasive pancreatic surgery in the European E-MIPS registry

HPB (Oxford). 2023 Apr;25(4):400-408. doi: 10.1016/j.hpb.2022.07.015. Epub 2022 Aug 17.

Abstract

Background: The European registry for minimally invasive pancreatic surgery (E-MIPS) collects data on laparoscopic and robotic MIPS in low- and high-volume centers across Europe.

Methods: Analysis of the first year (2019) of the E-MIPS registry, including minimally invasive distal pancreatectomy (MIDP) and minimally invasive pancreatoduodenectomy (MIPD). Primary outcome was 90-day mortality.

Results: Overall, 959 patients from 54 centers in 15 countries were included, 558 patients underwent MIDP and 401 patients MIPD. Median volume of MIDP was 10 (7-20) and 9 (2-20) for MIPD. Median use of MIDP was 56.0% (IQR 39.0-77.3%) and median use of MIPD 27.7% (IQR 9.7-45.3%). MIDP was mostly performed laparoscopic (401/558, 71.9%) and MIPD mostly robotic (234/401, 58.3%). MIPD was performed in 50/54 (89.3%) centers, of which 15/50 (30.0%) performed ≥20 MIPD annually. This was 30/54 (55.6%) centers and 13/30 (43%) centers for MIPD respectively. Conversion rate was 10.9% for MIDP and 8.4% for MIPD. Overall 90 day mortality was 1.1% (n = 6) for MIDP and 3.7% (n = 15) for MIPD.

Conclusion: Within the E-MIPS registry, MIDP is performed in about half of all patients, mostly using laparoscopy. MIPD is performed in about a quarter of patients, slightly more often using the robotic approach. A minority of centers met the Miami guideline volume criteria for MIPD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Laparoscopy* / adverse effects
  • Minimally Invasive Surgical Procedures
  • Pancreas / surgery
  • Pancreatectomy / adverse effects
  • Pancreatic Neoplasms* / surgery
  • Pancreaticoduodenectomy / adverse effects
  • Postoperative Complications / etiology
  • Registries
  • Robotic Surgical Procedures* / adverse effects
  • Treatment Outcome